´ëÇѽŰæÁ¤½ÅÀÇÇÐȸ 2023³âµµ Ãá°èÇмú´ëȸ (2ÀÏÂ÷) : 2023-04-21
±³À°ÀÏÀÚ : 2023-04-21
±³À°Àå¼Ò : ·Ôµ¥È£ÅÚ ¼¿ï ¼Ò°øµ¿
±³À°ÁÖÁ¦ : ´ëÇѽŰæÁ¤½ÅÀÇÇÐȸ 2023³âµµ Ãá°èÇмú´ëȸ (2ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇѽŰæÁ¤½ÅÀÇÇÐȸ
´ã´çÀÚ : ÀÓ´Ù½½
¿¬¶ôó : 02-537-6171
À̸ÞÀÏ : knpa3355@hanmail.net
±³À°Á¾·ù : Á¤½Å°Ç°ÀÇÇаú
Âü¼®¿¹»óÀοø : 1200¸í
Èñ¸ÁÆòÁ¡ : 5Á¡ (ÀÏ¹Ý 3Á¡ / Çʼö 2Á¡)
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 25 ½Ã°£ 45ºÐ
¼¼ºÎ¼ö°·á : 160,000¿ø
ºñ°í - »çÀüµî·Ï: Á¤È¸¿ø 120,000 / Àü°øÀÇ ¹× ±ºÀü¹®ÀÇ 70,000 / Á¤½Å°Ç°°ü·Ã ±Ù¹«ÀÚ¡¤´ëÇлý¡¤´ëÇпø»ý 70,000 / ÀϹÝ(Ÿ°ú ¼Ò¼Ó) 140,000 - ÇöÀåµî·Ï: Á¤È¸¿ø 140,000 / Àü°øÀÇ ¹× ±ºÀü¹®ÀÇ 90,000 / Á¤½Å°Ç°°ü·Ã ±Ù¹«ÀÚ¡¤´ëÇлý¡¤´ëÇпø»ý 90,000 / ÀϹÝ(Ÿ°ú ¼Ò¼Ó) 160,000
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04-21 Å©¸®½ºÅ»º¼·ë1 09:30~09:55 Differentiation of Digital Therapeutics in the digital health ecosystem; patient perspectives; regulation of DTx products Lani Hessen(Digital Therapeutics Alliance)
±³À°½Ã°£ 04-21 Å©¸®½ºÅ»º¼·ë1 09:55~10:20 Indications for use, clinical evidence, and optimizing healthcare delivery with DTx Pooja Raghani(Digital Therapeutics Alliance)
±³À°½Ã°£ 04-21 Å©¸®½ºÅ»º¼·ë1 10:20~10:45 Real-world clinical application of DTx Danny Kim(WELT)
Åä·Ð 04-21 Å©¸®½ºÅ»º¼·ë1 10:45~11:00 ÁúÀÇ ÀÀ´ä ()
±³À°½Ã°£ 04-21 Å©¸®½ºÅ»º¼·ë2 09:30~09:55 Á¤½Å°Ç°ÀÇÇаú Àǻ簡 ÁöÄѾßÇÒ °ñµå¿öÅÍ·êÀÇ ¼Ò°³ È«ÁøÇ¥(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 04-21 Å©¸®½ºÅ»º¼·ë2 09:55~10:20 ȯÀÚ¿ÍÀÇ boundary »ç·Ê¿Í À±¸®Àû Áöħ À̼±¿ì(Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 04-21 Å©¸®½ºÅ»º¼·ë2 10:20~10:45 ÀÇ·áÀ±¸®ÇÐÀÚ°¡ ¹Ù¶óº» Á¤½Å°Ç°ÀÇÇаú ÀÇ»çÀÇ À±¸® ¹®Á¦ ÀÌÀÏÇÐ(¿¬¼¼ÀÇ´ë ÀÇ·áÀ±¸®Çб³½Ç)
Åä·Ð 04-21 Å©¸®½ºÅ»º¼·ë2 10:45~11:00 ÁúÀÇ ÀÀ´ä ()
±³À°½Ã°£ 04-21 Å©¸®½ºÅ»º¼·ë3 09:30~09:55 Àú³Î¸®Áò°ú Æ®¶ó¿ì¸¶ ÀÌÁ¤¾Ö(SBS ±âÀÚ)
±³À°½Ã°£ 04-21 Å©¸®½ºÅ»º¼·ë3 09:55~10:20 ÀÌÅ¿ø Âü»ç¸¦ µ¹¾Æº¸´Ù-Æ®¶ó¿ì¸¶ ¿¹¹æÀ» À§ÇÑ ¾ð·ÐÀÇ ¿ªÇÒ ±èÀ¯³ª(±¹¹ÎÀϺ¸ »çȸºÎ)
±³À°½Ã°£ 04-21 Å©¸®½ºÅ»º¼·ë3 10:20~10:45 ¾ð·Ð°ú Á¤½Å°Ç° ÀÌ´Ù¿µ(±¹¸³Á¤½Å°Ç°¼¾ÅÍ)
Åä·Ð 04-21 Å©¸®½ºÅ»º¼·ë3 10:45~11:00 ÁúÀÇ ÀÀ´ä ()
±³À°½Ã°£ 04-21 ¿¡¸Þ¶öµå·ë 09:30~09:55 ÃÖ¸éÄ¡·áÀÇ ½Å°æ»ý¸®ÇÐÀû ÀÌÇØ ¼ºÇü¸ð(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 04-21 ¿¡¸Þ¶öµå·ë 09:55~10:20 Ãָ鼺 ÃøÁ¤: ÃÖ¸éÀ¯µµÃ´µµ ½ÇÁ¦ ½Ã¿¬(Live demonstration) º¯¿µµ·(º¯¿µµ·½Å°æÁ¤½Å°ú)
±³À°½Ã°£ 04-21 ¿¡¸Þ¶öµå·ë 10:20~10:45 Ãָ鰨¼ö¼ºÀÇ °úÇÐÀû ôµµ¿Í ÀÓ»ó Àû¿ë »ç·Ê ·ùÀçÇü(¿©¼öÀü³²º´¿ø)
Åä·Ð 04-21 ¿¡¸Þ¶öµå·ë 10:45~11:00 ÁúÀÇ ÀÀ´ä ()
±³À°½Ã°£ 04-21 »çÆÄÀ̾·ë2,3 09:30~09:50 ¼ºÀÎADHD ¿Ü·¡Áý´ÜÀÎÁöÇൿġ·á À̷аú ½ÇÁ¦ ¹Ý°ÇÈ£(°æÈñÀÇ´ë)
±³À°½Ã°£ 04-21 »çÆÄÀ̾·ë2,3 09:50~10:10 ¸¶À½Ã¬±è ±â¹Ý Ä¡·á ÀÌö¼ø(°æ»óÀÇ´ë)
±³À°½Ã°£ 04-21 »çÆÄÀ̾·ë2,3 10:10~10:30 ÀÎÁö ÈÆ·Ã – ÀÛ¾÷±â¾ïÈÆ·ÃÀ» Áß½ÉÀ¸·Î À¯ÇÑÀÍ(¼¿ï¿ì¸®¾ÆÀÌÁ¤½Å°Ç°ÀÇÇаúÀÇ¿ø)
±³À°½Ã°£ 04-21 »çÆÄÀ̾·ë2,3 10:30~10:50 µðÁöÅÐ ±â¹Ý Æò°¡ ¹× Ä¡·á ÇÑ´öÇö(Áß¾ÓÀÇ´ë)
Åä·Ð 04-21 »çÆÄÀ̾·ë2,3 10:50~11:00 ÁúÀÇ ÀÀ´ä ()
±³À°½Ã°£ 04-21 »çÆÄÀ̾·ë4 09:30~09:55 Áßµ¶°ú ¹®È, ÁøÈÀû °üÁ¡ °¿õ±¸(¼¿ïÀÇ´ë)
±³À°½Ã°£ 04-21 »çÆÄÀ̾·ë4 09:55~10:20 ¾ËÄڿà ȯÀÚµéÀÇ ¹«ÀǽĿ¡¼ ÀϾ°í ÀÖ´Â Ä¡À¯Àû¡¤Ã¢Á¶Àû »ç°Çµé ¹é±âÈ«(¿ï»ê±âµ¶º´¿ø)
±³À°½Ã°£ 04-21 »çÆÄÀ̾·ë4 10:20~10:45 ºÐ¼®½É¸®ÇÐÀû °üÁ¡¿¡¼ ¹Ù¶óº» ¾ËÄÚ¿Ã Áßµ¶ ÀÌ»óÀÍ(ÃæºÏÀÇ´ë)
Åä·Ð 04-21 »çÆÄÀ̾·ë4 10:45~11:00 ÁúÀÇ ÀÀ´ä ()
±³À°½Ã°£ 04-21 Å©¸®½ºÅ»º¼·ë1,2,3 11:10~12:00 ´ëÇѹα¹ ÀÓ»ó½Å°æÁ¤½Å¾à¹°ÇÐÀÇ ¿ª»ç: ÁÖ¿ä Á¤½ÅÁúȯÀ» Áß½ÉÀ¸·Î ¹Ú¿ø¸í(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 04-21 Å©¸®½ºÅ»º¼·ë1 12:20~12:45 ¼Ò¾Æû¼Ò³â ADHD¿¡¼ MPH-OROSÀÇ ÀÓ»óÀû À¯¿ë¼º ±èÀÎÇâ(ÇѾçÀÇ´ë)
±³À°½Ã°£ 04-21 Å©¸®½ºÅ»º¼·ë1 12:45~13:10 ¼ºÀÎ ADHDÀÇ Áø´Ü ¹× Ä¡·áÀü·« ¼ºÇü¸ð(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 04-21 Å©¸®½ºÅ»º¼·ë3 12:20~12:45 The Modern Perspective for Long-acting Injectables Antipsychotics in the Patient-centered Care of Schizophrenia ¿À»óÈÆ(À»ÁöÀÇ´ë)
±³À°½Ã°£ 04-21 Å©¸®½ºÅ»º¼·ë3 12:45~13:10 Optimal Treatment Option for Changing AP Polypharmacy Practices in Maintenance Phase Schizophrenia ÀÌÁØÈñ(À»ÁöÀÇ´ë)
±âŸ 04-21 »çÆÄÀ̾·ë2,3 13:00~13:50 Á¤½Å°Ç°ÀÇÇаú Àü°øÀÇ ¿¬Â÷º° ¼ö·Ã¸ñÇ¥ ¹× ¼ö·Ã±³°ú°úÁ¤ ±èÅÂÈñ(¿øÁÖ¼¼ºê¶õ½º±âµ¶º´¿ø, ¼ö·Ã°£»ç)
±âŸ 04-21 »çÆÄÀ̾·ë2,3 13:50~14:40 Á¤½Å°Ç°ÀÇÇаú ¼ö·Ã±³À° ¹ßÀüÀ» À§ÇÑ °í½ÃÁ¦µµ ±è¼º¿Ï(Àü³²ÀÇ´ë, °í½ÃÀÌ»ç)
±âŸ 04-21 »çÆÄÀ̾·ë2,3 14:50~15:40 Á¤½Å°Ç°ÀÇÇаú ¼ö·Ã±ÔÁ¤ ¹× ¼ö·Ã½ÇŽɻç±âÁØ °Àç¸í(°¡ÃµÀÇ´ë, ¼ö·Ã°£»ç)
±âŸ 04-21 »çÆÄÀ̾·ë2,3 15:40~16:30 ¿Â¶óÀÎ Àü°øÀÇ ±³À°½Ã½ºÅÛ È°¿ë¾È³» Àü¸í¿í(±¹¸³Áß¾ÓÀÇ·á¿ø, ¼ö·Ã°£»ç)
Åä·Ð 04-21 »çÆÄÀ̾·ë2,3 16:30~17:00 ÁúÀÇÀÀ´ä ¹× Åä·Ð ()
±³À°½Ã°£ 04-21 Å©¸®½ºÅ»º¼·ë1 13:40~14:25 Á¤½ÅÀÇÇаú ÀηùÇÐ ¹ÚÇѼ±(¼¿ï´ëÇб³ ÀηùÇаú)
±³À°½Ã°£ 04-21 Å©¸®½ºÅ»º¼·ë2 13:40~14:00 °¡Ä¡ÀÛ¾÷ÀÇ ¿ª»ç¿Í ÀÇ¹Ì ³ªÀÇÇö(¿¹¼öº´¿ø)
±³À°½Ã°£ 04-21 Å©¸®½ºÅ»º¼·ë2 14:00~14:20 µ¿±â¸é´ã¿¡¼ÀÇ °¡Ä¡ÀÛ¾÷ ¹é¼öÇö(°è¿äº´¿ø)
±³À°½Ã°£ 04-21 Å©¸®½ºÅ»º¼·ë2 14:20~14:40 ÀǹÌÄ¡·á(·Î°íÅ׶óÇÇ)¿¡¼ÀÇ °¡Ä¡ÀÛ¾÷ À̽¿ì(±¹±ºÆ÷õº´¿ø)
±³À°½Ã°£ 04-21 Å©¸®½ºÅ»º¼·ë2 14:40~15:00 ¼ö¿ëÀü³äÄ¡·á¿¡¼ÀÇ °¡Ä¡ÀÛ¾÷ ¼Çõ¼ö(°ºÏ»ï¼ºº´¿ø ±â¾÷Á¤½Å°Ç°¿¬±¸¼Ò)
Åä·Ð 04-21 Å©¸®½ºÅ»º¼·ë2 15:00~15:10 ÁúÀÇ ÀÀ´ä ()
±³À°½Ã°£ 04-21 Å©¸®½ºÅ»º¼·ë3 13:40~14:00 ³úÆĽÅÈ£¸¦ ÀÌ¿ëÇÑ ÀΰøÁö´É ±â¼ú ±â¹Ý ÁÖ¿ä¿ì¿ïÁõ Áø´Ü ȲÇÑÁ¤(°í·Á´ëÇб³ ÀüÀÚ¹×Á¤º¸°øÇаú)
±³À°½Ã°£ 04-21 Å©¸®½ºÅ»º¼·ë3 14:00~14:20 ³úÆÄ ½ÅÈ£ ÀÌ¿ë ÁÖ¿ä¿ì¿ïÁõ Ä¡·á¹ÝÀÀ¼º ¾ÆÇüºÐ·ù ÃÖ°¹Î(ÀÓ»ó°¨Á¤ÀÎÁö±â´É¿¬±¸¼Ò/ÇѾç´ëÇб³ °è»êÁö´É ¹× ³ú°øÇÐ ¿¬±¸½Ç)
±³À°½Ã°£ 04-21 Å©¸®½ºÅ»º¼·ë3 14:20~14:40 2ä³Î ³úÆĸ¦ ÀÌ¿ëÇÑ biotypeÀÇ À¯¿ë¼º: ¸¶À½°á EBSI ¼Ò°³ À̽Âȯ(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 04-21 Å©¸®½ºÅ»º¼·ë3 14:40~15:00 ´ëÇѹα¹ µðÁöÅÐ ÇコÄÉ¾î ½ÃÀåÀÇ ¹Ì·¡¿Í ¹ßÀü ¹æÇâ ÃÖ³«Ãµ(KBÇコÄÉ¾î ´ëÇ¥)
Åä·Ð 04-21 Å©¸®½ºÅ»º¼·ë3 15:00~15:10 ÁúÀÇ ÀÀ´ä ()
±³À°½Ã°£ 04-21 ¿¡¸Þ¶öµå·ë 13:40~14:00 °Ç°º¸Çè½É»çÆò°¡¿ø û±¸ÀڷḦ ÀÌ¿ëÇÑ ¾à¹°Ä¡·á ÇöȲ ÁÖ¼º¿ì(¿ï»êÀÇ´ë)
±³À°½Ã°£ 04-21 ¿¡¸Þ¶öµå·ë 14:00~14:20 Àå±âÁö¼ÓÇü ÁÖ»çÁ¦ »ç¿ëÀÇ ½ÇÁ¦ ¿À»óÈÆ(À»ÁöÀÇ´ë)
±³À°½Ã°£ 04-21 ¿¡¸Þ¶öµå·ë 14:20~14:40 Ä¡·áÀúÇ×¼º Á¶Çöº´ÀÇ ¾à¹° Ä¡·á ±è¼¼Çö(¼¿ïÀÇ´ë)
±³À°½Ã°£ 04-21 ¿¡¸Þ¶öµå·ë 14:40~15:00 Á¶Çöº´ÀÇ »õ·Î¿î ¾à¹° Ä¡·áÁ¦ ÇöȲ ÀÌÁß¼±(¿ï»êÀÇ´ë)
Åä·Ð 04-21 ¿¡¸Þ¶öµå·ë 15:00~15:10 ÁúÀÇ ÀÀ´ä ()
±³À°½Ã°£ 04-21 »çÆÄÀ̾·ë4 13:40~13:55 Multimodal prediction of treatment-resistance in patients with depression leveraging brain morphometry and natural language processing À̵¿À±(¾ÆÁÖÀÇ´ë)
±³À°½Ã°£ 04-21 »çÆÄÀ̾·ë4 13:55~14:10 Emotional recognition deficits in patients with bipolar I disorder and their unaffected first-degree relatives Á¶ÁöÇö(°æºÏÀÇ´ë)
±³À°½Ã°£ 04-21 »çÆÄÀ̾·ë4 14:10~14:25 Effectiveness of digital therapeutics specialized in executive functions as adjunctive treatment for clinical symptoms of attention-deficit/hyperactivity disorder: A neuropsychological assessment of feasibility study ¼ÕÅÂÇý(°í·ÁÀÇ´ë)
±³À°½Ã°£ 04-21 »çÆÄÀ̾·ë4 14:25~14:40 Exploration of neuroanatomical characteristics relating to progression from preclinical to prodromal Alzheimer ±èÇÐÇö(¼¿ïÀÇ´ë)
±³À°½Ã°£ 04-21 »çÆÄÀ̾·ë4 14:40~14:55 Altered cortical gyrification as a predictive marker of treatment resistance in patients with first-episode psychosis Àå¹®¿µ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 04-21 Å©¸®½ºÅ»º¼·ë1 14:40~15:25 °Ç°ÇÑ Àΰ£ °³³äÀÇ ÇÑ Ç¥ÁØ ¸ðµ¨ -¸¸»çÇüÅëÇü ¸ðµ¨- Á¶¼öö(¼¿ïÀÇ´ë ¸í¿¹±³¼ö)
±³À°½Ã°£ 04-21 Å©¸®½ºÅ»º¼·ë2 15:20~15:45 À¯¿£³¹Î±â±¸ÀÇ È°µ¿°ú ³¹Î Á¤½Å°Ç° À̽´ ÀÌŹ°Ç(À¯¿£³¹Î±â±¸)
±³À°½Ã°£ 04-21 Å©¸®½ºÅ»º¼·ë2 15:45~16:15 ±¹³» ³¹ÎÀÇ Á¤½Å°Ç° ¼ºñ½º Á¢±Ù ½ÇÅÂ¿Í °úÁ¦ ±è¿µ¾Æ(¾Æ½Ã¾ÆÆòȸ¦ÇâÇÑÀÌÁÖ MAP ´ëÇ¥)
±³À°½Ã°£ 04-21 Å©¸®½ºÅ»º¼·ë2 16:15~16:40 ÀÌÁֹΰú ³¹ÎÀÇ Á¤½Å°Ç°¿¡ ´ëÇÑ ÀÓ»óÀû Á¢±Ù ÀÌö¼ø(°æ»óÀÇ´ë)
Åä·Ð 04-21 Å©¸®½ºÅ»º¼·ë2 16:40~16:50 ÁúÀÇ ÀÀ´ä ()
±³À°½Ã°£ 04-21 Å©¸®½ºÅ»º¼·ë3 15:20~16:20 ÀÇ»çÀÇ ÀÌÇØ»óÃæ°ú ±× °ü¸®: ÀÇ·áºÐÀïÀ» Áß½ÉÀ¸·Î ÀÌÀÏÇÐ(¿¬¼¼´ëÇб³ Àι®»çȸÀÇÇб³½Ç)
±³À°½Ã°£ 04-21 Å©¸®½ºÅ»º¼·ë3 16:20~17:20 Á¦ 5Â÷ Àڻ쿹¹æ±âº»°èȹ(23-27)°ú ÀÇ·á¹ý·É Á¤Ã¥ ¹æÇâ ȲÅ¿¬(Çѱ¹»ý¸íÈñ¸ÁÁ¸ÁßÀç´Ü)
±³À°½Ã°£ 04-21 ¿¡¸Þ¶öµå·ë 15:20~16:00 »ç·Ê ¹ßÇ¥: ¾î¸Ó´Ï¸¦ ÅëÇÑ Áß 3 ÇлýÀÇ Ä¡·á »ç·Ê À̵¿¿ì(ÀÎÁ¦ÀÇ´ë)
Åä·Ð 04-21 ¿¡¸Þ¶öµå·ë 16:00~16:10 »ç·Ê Åä·Ð: ¼¿ï Àΰ£°ü°è Á¤½ÅºÐ¼®ÇÐȸÀÇ ½Ã°¢ À̹ü¿ë(À̹ü¿ë½Å°æÁ¤½Å°ú)
Åä·Ð 04-21 ¿¡¸Þ¶öµå·ë 16:10~16:20 »ç·Ê Åä·Ð: ºÐ¼®Ä¡·áÇÐȸÀÇ ½Ã°¢ ÀÌÁ¤¹ü(°¡Á·»ç¶û¼¿ïÁ¤½Å°Ç°ÀÇÇаúÀÇ¿ø)
Åä·Ð 04-21 ¿¡¸Þ¶öµå·ë 16:20~16:30 »ç·Ê Åä·Ð: ºÐ¼®½É¸®ÇÐȸÀÇ ½Ã°¢ ±èÁö¿¬(ÁÁÀº¸¶À½Á¤½Å°Ç°ÀÇÇаúÀÇ¿ø)
Åä·Ð 04-21 ¿¡¸Þ¶öµå·ë 16:30~16:40 »ç·Ê Åä·Ð: Á¤½ÅÄ¡·áÇÐȸÀÇ ½Ã°¢ ¿ìÁ¤¹Î(°æºÏÀÇ´ë)
Åä·Ð 04-21 ¿¡¸Þ¶öµå·ë 16:40~17:00 Àüü Åä·Ð ()
±³À°½Ã°£ 04-21 »çÆÄÀ̾·ë4 15:20~16:00 Áßµ¶È¯ÀÚ¿¡¼ µ¿±â°ÈÄ¡·á ³ªÀÇÇö(¿¹¼öº´¿ø)
±³À°½Ã°£ 04-21 »çÆÄÀ̾·ë4 16:00~16:40 ¾ËÄÚ¿Ã ´ã¹è »ç¿ëÀå¾ÖÀÇ ¾à¹°Ä¡·á Á¤Á¶Àº(°¡Å縯ÀÇ´ë)